Cargando…
Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region
BACKGROUND: Individualized treatment for multidrug-resistant tuberculosis (MDR TB) is associated with improved outcomes. Therapy needs to be tailored to drug susceptibility testing (DST) results. We present our observations on the inconsistency in DST reporting in an endemic region with a high preva...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592753/ https://www.ncbi.nlm.nih.gov/pubmed/28869226 http://dx.doi.org/10.4103/0970-2113.213840 |
_version_ | 1783262934429859840 |
---|---|
author | Saha, Avinandan Vaidya, Preyas J Chavhan, Vinod B Pandey, Kamlesh V Kate, Arvind H Chhajed, Prashant N |
author_facet | Saha, Avinandan Vaidya, Preyas J Chavhan, Vinod B Pandey, Kamlesh V Kate, Arvind H Chhajed, Prashant N |
author_sort | Saha, Avinandan |
collection | PubMed |
description | BACKGROUND: Individualized treatment for multidrug-resistant tuberculosis (MDR TB) is associated with improved outcomes. Therapy needs to be tailored to drug susceptibility testing (DST) results. We present our observations on the inconsistency in DST reporting in an endemic region with a high prevalence of MDR TB. METHODS: We retrospectively analyzed 118 DST reports from 10 different laboratories. OBSERVATIONS: Of 118 patients, only 79 (67%) had DST reports with results to all first-line drugs, a fluoroquinolone (excluding ciprofloxacin), all aminoglycosides, and a polypeptide. Twenty-one (18%) isolates did not have DST reports for all first-line drugs; 4 (3%) did not have DST reports for any second-line drugs; 9 (8%) did not have DST reports for a fluoroquinolone; and 31 (26%) did not have DST reports for all second-line aminoglycosides and polypeptide. CONCLUSION: Inconsistencies were observed in several of the 118 DST reports. A case is made for sensitization toward standardization and completeness in TB DST reporting in India. |
format | Online Article Text |
id | pubmed-5592753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-55927532017-09-19 Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region Saha, Avinandan Vaidya, Preyas J Chavhan, Vinod B Pandey, Kamlesh V Kate, Arvind H Chhajed, Prashant N Lung India Original Article BACKGROUND: Individualized treatment for multidrug-resistant tuberculosis (MDR TB) is associated with improved outcomes. Therapy needs to be tailored to drug susceptibility testing (DST) results. We present our observations on the inconsistency in DST reporting in an endemic region with a high prevalence of MDR TB. METHODS: We retrospectively analyzed 118 DST reports from 10 different laboratories. OBSERVATIONS: Of 118 patients, only 79 (67%) had DST reports with results to all first-line drugs, a fluoroquinolone (excluding ciprofloxacin), all aminoglycosides, and a polypeptide. Twenty-one (18%) isolates did not have DST reports for all first-line drugs; 4 (3%) did not have DST reports for any second-line drugs; 9 (8%) did not have DST reports for a fluoroquinolone; and 31 (26%) did not have DST reports for all second-line aminoglycosides and polypeptide. CONCLUSION: Inconsistencies were observed in several of the 118 DST reports. A case is made for sensitization toward standardization and completeness in TB DST reporting in India. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5592753/ /pubmed/28869226 http://dx.doi.org/10.4103/0970-2113.213840 Text en Copyright: © 2017 Indian Chest Society http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Saha, Avinandan Vaidya, Preyas J Chavhan, Vinod B Pandey, Kamlesh V Kate, Arvind H Chhajed, Prashant N Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
title | Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
title_full | Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
title_fullStr | Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
title_full_unstemmed | Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
title_short | Inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
title_sort | inconsistency in the reporting of antitubercular drug susceptibility tests in an endemic region |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592753/ https://www.ncbi.nlm.nih.gov/pubmed/28869226 http://dx.doi.org/10.4103/0970-2113.213840 |
work_keys_str_mv | AT sahaavinandan inconsistencyinthereportingofantituberculardrugsusceptibilitytestsinanendemicregion AT vaidyapreyasj inconsistencyinthereportingofantituberculardrugsusceptibilitytestsinanendemicregion AT chavhanvinodb inconsistencyinthereportingofantituberculardrugsusceptibilitytestsinanendemicregion AT pandeykamleshv inconsistencyinthereportingofantituberculardrugsusceptibilitytestsinanendemicregion AT katearvindh inconsistencyinthereportingofantituberculardrugsusceptibilitytestsinanendemicregion AT chhajedprashantn inconsistencyinthereportingofantituberculardrugsusceptibilitytestsinanendemicregion |